These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6671796)

  • 1. Therapy of anaerobic infections.
    Wilkins TD; West SE
    Infection; 1983; 11 Suppl 2():S105-8. PubMed ID: 6671796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
    Brook I; Ledney GD
    J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Identification of anaerobic bacteria isolated from various clinical specimens and determination of antibiotic susceptibilities].
    Doğan M; Baysal B
    Mikrobiyol Bul; 2010 Apr; 44(2):211-9. PubMed ID: 20549955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
    Brook I
    Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
    Bartlett JG; Dezfulian M; Joiner K
    Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.
    Moody JA; Fasching CE; Sinn LM; Gerding DN; Peterson LR
    J Lab Clin Med; 1990 Feb; 115(2):190-5. PubMed ID: 1967626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
    Thadepalli H; Chuah SK; Gollapudi S
    Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model.
    Alder J; Clement JJ
    J Antimicrob Chemother; 1993 Feb; 31(2):303-11. PubMed ID: 8463174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in the management of anaerobic infections.
    Bartlett JG
    Rev Infect Dis; 1983; 5(2):235-45. PubMed ID: 6844805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance and resistance transfer in anaerobic bacteria: factors influencing antimicrobial therapy.
    Tally FP; Cuchural GJ; Malamy MH
    Rev Infect Dis; 1984; 6 Suppl 1():S260-9. PubMed ID: 6326243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of anaerobic infections.
    Finegold SM; Bartlett JG; Chow AW; Flora DJ; Gorbach SL; Harder EJ; Tally FP
    Ann Intern Med; 1975 Sep; 83(3):375-89. PubMed ID: 1190633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
    Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
    J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic treatment of anaerobic infections.
    Gorbach SL
    Clin Infect Dis; 1994 May; 18 Suppl 4():S305-10. PubMed ID: 8086580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infections by anaerobes in children: frequency of isolation and antimicrobial resistance].
    Leaños B; Guiscafré H; Guerra R; Sandoval M; Rubí S; Trejo JA; Zúñiga V
    Bol Med Hosp Infant Mex; 1989 Jul; 46(7):455-62. PubMed ID: 2788434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for infections due to anaerobic bacteria: an overview.
    Finegold SM
    J Infect Dis; 1977 Mar; 135 Suppl():S25-9. PubMed ID: 321708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital.
    Tan TY; Ng LS; Kwang LL; Rao S; Eng LC
    Anaerobe; 2017 Feb; 43():69-74. PubMed ID: 27890724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic therapy for anaerobic infections.
    Weber SJ; Lefrock JL
    Am Fam Physician; 1985 Apr; 31(4):212-6. PubMed ID: 3984824
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of antimicrobial therapy on mixed infections with Bacteroides species. Is eradication of the anaerobes important?
    Brook I
    J Infect; 1991 Jan; 22(1):27-35. PubMed ID: 2002230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of anaerobic infections: an overview.
    Finegold SM
    Scand J Infect Dis Suppl; 1985; 46():89-95. PubMed ID: 3865355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
    Goldstein EJ; Solomkin JS; Citron DM; Alder JD
    Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.